Cas:22855-57-8 3-(3-bromophenyl)pyrrolidine-2,5-dione manufacturer & supplier

We serve Chemical Name:3-(3-bromophenyl)pyrrolidine-2,5-dione CAS:22855-57-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-(3-bromophenyl)pyrrolidine-2,5-dione

Chemical Name:3-(3-bromophenyl)pyrrolidine-2,5-dione
CAS.NO:22855-57-8
Synonyms:3-(3-Bromophenyl)-2,5-pyrrolidinedione;Brosuximide;Brosuximida [INN-Spanish];2-(m-Bromophenyl)succinimide;Imid kwasu 3-bromofenylobursztynowego [Polish];3-Bromophenylsuccinimide;3-(3-bromophenyl)-pyrrolidine-2,5-dione;m-Bromophenylsuccinimide;Succinimide,2-(m-bromophenyl);Brosuximidum [INN-Latin]
Molecular Formula:C10H8BrNO2
Molecular Weight:254.08000
HS Code:2925190090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:425.7ºC at 760mmHg
Density:1.606g/cm3
Index of Refraction:1.601
PSA:49.66000
Exact Mass:252.97400
LogP:1.85510

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-(3-Bromophenyl)-2,5-pyrrolidinedione chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Brosuximidum [INN-Latin] physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Brosuximida [INN-Spanish] Use and application,Brosuximide technical grade,usp/ep/jp grade.


Related News: With no new systemic lupus erythematosus treatments in over a decade, we’re working to make this new medicine available as soon as possible.” 1′-Cyanoaethyl-4,6-di-O-acetyl-2,3-didesoxy-α-D-erythro-hexen-2-pyranosid manufacturers Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said: “The data being presented at EULAR add to the growing body of evidence for anifrolumab that demonstrate a compelling clinical profile with the potential to address significant unmet medical needs in this debilitating disease. N,N-dimethyl-4-[1-(3-nitro-phenyl)-benzo[f]quinolin-3-yl]-aniline suppliers Wavelength Pharmaceuticals will pay an undisclosed sum to buy up a majority stake in Hyderabad’s Vanamali Organics, an Indian firm specializing in making drug intermediates and starting materials that will add to Wavelengths’ API contract manufacturing work, the company said in a release. 1H-Tetrazole, 5-[4-(3,4-dichloro-2-propylphenoxy)butyl]- vendor & factory.